An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer

Stopped study did not meet pre-specified criteria for continuation following interim futility analysis

Conditions

• Ovarian Cancer

Interventions

• DRUG: MORAb-003 (farletuzumab)
• DRUG: 0.9% Saline
• DRUG: Paclitaxel

Sponsor

Morphotek